| One-third of reef-building corals face elevated extinction risk from climate change and local impacts KE Carpenter, M Abrar, G Aeby, RB Aronson, S Banks, A Bruckner, ... Science 321 (5888), 560-563, 2008 | 1777 | 2008 |
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL H Kantarjian, F Giles, L Wunderle, K Bhalla, S O'Brien, B Wassmann, ... New England Journal of Medicine 354 (24), 2542-2551, 2006 | 1651 | 2006 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1537 | 2006 |
| Molecular biology of bcr-abl1–positive chronic myeloid leukemia A Quintás-Cardama, J Cortes Blood, The Journal of the American Society of Hematology 113 (8), 1619-1630, 2009 | 930 | 2009 |
| Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera A Quintás-Cardama, H Kantarjian, T Manshouri, R Luthra, Z Estrov, ... Journal of Clinical Oncology 27 (32), 5418-5424, 2009 | 523 | 2009 |
| A reef under siltation stress: Cahuita, Costa Rica JN Cortés, MJ Risk Bulletin of Marine Science 36 (2), 339-356, 1985 | 519 | 1985 |
| Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele, S O'brien, X Zhou, ... Leukemia 20 (10), 1767-1773, 2006 | 507 | 2006 |
| Epidemiology of candidemia in Latin America: a laboratory-based survey M Nucci, F Queiroz-Telles, T Alvarado-Matute, IN Tiraboschi, J Cortes, ... PloS one 8 (3), e59373, 2013 | 488 | 2013 |
| Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia H Kantarjian, F Ravandi, S O'Brien, J Cortes, S Faderl, G Garcia-Manero, ... Blood, The Journal of the American Society of Hematology 116 (22), 4422-4429, 2010 | 479 | 2010 |
| Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience H Kantarjian, S O'Brien, E Jabbour, G Garcia-Manero, ... Blood, The Journal of the American Society of Hematology 119 (9), 1981-1987, 2012 | 477 | 2012 |
| MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation FJ Giles, J Cortes, D Jones, D Bergstrom, H Kantarjian, SJ Freedman Blood 109 (2), 500-502, 2007 | 465 | 2007 |
| Marine biodiversity in the Caribbean: regional estimates and distribution patterns P Miloslavich, JM Díaz, E Klein, JJ Alvarado, C Díaz, J Gobin, ... PloS one 5 (8), e11916, 2010 | 461 | 2010 |
| Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia W Zhang, M Konopleva, Y Shi, T McQueen, D Harris, X Ling, Z Estrov, ... JNCI: Journal of the National Cancer Institute 100 (3), 184-198, 2008 | 459 | 2008 |
| Reef coral reproduction in the eastern Pacific: Costa Rica, Panama, and Galapagos Islands (Ecuador) I. Pocilloporidae PW Glynn, NJ Gassman, CM Eakin, J Cortes, DB Smith, HM Guzman Marine Biology 109, 355-368, 1991 | 405* | 1991 |
| Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase T Hughes, G Saglio, S Branford, S Soverini, DW Kim, MC Müller, ... Journal of clinical oncology 27 (25), 4204-4210, 2009 | 392 | 2009 |
| A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies F Giles, T Fischer, J Cortes, G Garcia-Manero, J Beck, F Ravandi, ... Clinical Cancer Research 12 (15), 4628-4635, 2006 | 379 | 2006 |
| Flying under the radar: the new wave of BCR–ABL inhibitors A Quintás-Cardama, H Kantarjian, J Cortes Nature Reviews Drug Discovery 6 (10), 834-848, 2007 | 368 | 2007 |
| Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond A Quintás-Cardama, H Kantarjian, J Cortes, S Verstovsek Nature reviews Drug discovery 10 (2), 127-140, 2011 | 359 | 2011 |
| Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML CD DiNardo, F Ravandi, S Agresta, M Konopleva, K Takahashi, T Kadia, ... American journal of hematology 90 (8), 732-736, 2015 | 353 | 2015 |
| Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype N Jain, AV Lamb, S O’Brien, F Ravandi, M Konopleva, E Jabbour, Z Zuo, ... Blood, The Journal of the American Society of Hematology 127 (15), 1863-1869, 2016 | 347 | 2016 |
